Proprietary AI analyst is now available
- Public Comps
- Novogene
Novogene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Novogene and similar public comparables like New Horizon Health, Maravai LifeSciences, Diagnósticos da América, Castle Biosciences and more.
Novogene Overview
About Novogene
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
Founded
2011
HQ

Employees
N/A
Website
Financials (LTM)
EV
$589M
Valuation Multiples
Start free trialNovogene Financials
Novogene reported last 12-month revenue of $340M and EBITDA of $50M.
In the same LTM period, Novogene generated $145M in gross profit, $50M in EBITDA, and $27M in net income.
Revenue (LTM)
Novogene P&L
In the most recent fiscal year, Novogene reported revenue of $326M and EBITDA of $51M.
Novogene is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 16%, and net margin of 8%.
Financial data powered by Morningstar, Inc.
Novogene Stock Performance
Novogene has current market cap of $819M, and enterprise value of $589M.
Market Cap Evolution
Novogene's stock price is $1.97.
Novogene share price decreased by 5.7% in the last 30 days, and by 4.0% in the last year.
Novogene has an EPS (earnings per share) of $0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $589M | $819M | -3.5% | -5.7% | -3.4% | -4.0% | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNovogene Valuation Multiples
Novogene trades at 1.7x EV/Revenue multiple, and 11.7x EV/EBITDA.
EV / Revenue (LTM)
Novogene Financial Valuation Multiples
As of June 5, 2026, Novogene has market cap of $819M and EV of $589M.
Novogene has a P/E ratio of 29.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Novogene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Novogene Margins & Growth Rates
Novogene grew revenue by 11% and EBITDA by 9% in the last fiscal year.
In the most recent fiscal year, Novogene reported gross margin of 43%, EBITDA margin of 16%, and net margin of 8%.
Novogene Margins
Novogene Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Novogene Operational KPIs
Novogene's Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novogene's Rule of X is 42% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Novogene Competitors
Novogene competitors include New Horizon Health, Maravai LifeSciences, Diagnósticos da América, Castle Biosciences, Vazyme Biotech, Jiangsu Bioperfectus, Assure Tech, Azenta, Clinica Baviera and Fulgent Genetics.
Most Novogene public comparables operate across Laboratory Services, Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| 4.5x | 4.3x | (27.0x) | (178.2x) | |||
| 0.9x | 1.0x | 4.7x | 4.7x | |||
| 1.2x | 1.2x | 10.0x | 16.8x | |||
| 3.6x | 3.4x | 34.3x | 21.4x | |||
| 8.8x | - | 90.4x | - | |||
| 5.2x | - | 19.0x | - | |||
| 1.2x | 1.2x | 11.0x | 11.7x | |||
This data is available for Pro users. Sign up to see all Novogene competitors and their valuation data. Start Free Trial | ||||||
Novogene VC Funding History
Before going public, Novogene raised $75M in total equity funding, across 1 round.
Novogene Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Novogene
| When was Novogene founded? | Novogene was founded in 2011. |
| Where is Novogene headquartered? | Novogene is headquartered in China. |
| Is Novogene publicly listed? | Yes, Novogene is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Novogene? | Novogene trades under 688315 ticker. |
| When did Novogene go public? | Novogene went public in 2021. |
| Who are competitors of Novogene? | Novogene main competitors include New Horizon Health, Maravai LifeSciences, Diagnósticos da América, Castle Biosciences, Vazyme Biotech, Jiangsu Bioperfectus, Assure Tech, Azenta, Clinica Baviera, Fulgent Genetics. |
| What is the current market cap of Novogene? | Novogene's current market cap is $819M. |
| What is the current revenue of Novogene? | Novogene's last 12 months revenue is $340M. |
| What is the current revenue growth of Novogene? | Novogene revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Novogene? | Current revenue multiple of Novogene is 1.7x. |
| What is the current EBITDA of Novogene? | Novogene's last 12 months EBITDA is $50M. |
| What is Novogene's EBITDA margin? | Novogene's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Novogene? | Current EBITDA multiple of Novogene is 11.7x. |
| How many companies Novogene has acquired to date? | Novogene hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Novogene has invested to date? | Novogene hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Novogene
Lists including Novogene
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.